# US drug agency approves breakthrough treatment for pancreatic cancer

- URL: https://talkfuse.com/story/us-drug-agency-approves-breakthrough-treatment-for-pancreatic-cancer/
- Published: 2026-08-27T09:37:11+00:00
- Updated: 2026-08-27T15:44:06+00:00
- Original publisher: BBC World (publisher lean: Centre)
- Original article: https://www.bbc.co.uk/news/articles/clyq4ge4wk9o?at_medium=RSS&amp;at_campaign=rss
- Topics: Americas, Health, Medicine, World

## Key points

- FDA approves pancreatic cancer drug after strong survival results
- Trial survival averaged 13.2 months versus 6.6 with chemotherapy
- Drug targets KRAS mutations common in pancreatic tumours

## Summary

The US Food and Drug Administration has approved daraxonrasib, sold as Rasonque, for pancreatic cancer after a late-stage trial found it nearly doubled average survival compared with chemotherapy. The decision provides a new option for a cancer that is frequently diagnosed late, has the highest mortality rate among major cancers and has historically been difficult to treat.

In a 500-patient trial, people taking the daily pill lived for an average of 13.2 months, compared with 6.6 months for those receiving chemotherapy. The drug targets mutated KRAS, found in more than 90% of pancreatic tumours; severe side effects affected 44% of patients taking it, against 57.5% on chemotherapy, while common effects included rash, diarrhoea, nausea, fatigue and vomiting.

## Coverage

- [BBC World: US drug agency approves breakthrough treatment for pancreatic cancer](https://www.bbc.co.uk/news/articles/clyq4ge4wk9o?at_medium=RSS&amp;at_campaign=rss)
- [NPR: FDA approves landmark pancreatic cancer drug that's shown to improve survival](https://www.npr.org/2026/08/27/g-s1-140410/fda-approves-landmark-pancreatic-cancer-drug)

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
